



**For Immediate Release**  
**January 14, 2021**

**SUNSHINE BIOPHARMA RECEIVES FOURTH TRANCHE FROM PREVIOUSLY  
ANNOUNCED \$2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT**

Montreal, Quebec, Canada -- (ACCESSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: "SBFM"), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received the fourth tranche of funding under the recently announced committed minimum financing of \$2,000,000 with RB Capital Partners Inc. This brings the total to \$1,050,000 that the Company has received to date under this financing. The proceeds will be used for the ongoing development of the Company's Coronavirus Treatment on a priority basis and the clinical development of Adva-27a, the Company's flagship anticancer compound targeted for pancreatic cancer.

Sunshine Biopharma Inc. CFO, Camille Sebaaly stated, "As a company, we continue to forge forward in our development of a COVID treatment and our anticancer compounds. This investment capital has been integral to our progress in each of these sectors."

Brett Rosen and Deborah Braun of RB Capital Partners Inc. stated, "We are very impressed with the Sunshine leadership team and their commitment to developing critical life-saving medical treatments. Our investment money has been met with ongoing milestones and we are pleased to be considered a long-term funding partner of the Company. We are looking forward to a potential up-list to the Nasdaq in the future."

**About Sunshine Biopharma's Coronavirus Treatment**

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 1.9 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine Biopharma filed a provisional patent application for several molecules which were designed by computer-aided modeling to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to multiply. Sunshine Biopharma has since completed the synthesis of four such molecules and identified a lead compound, SBFM-PL4. In collaboration with the University of Georgia, College of Pharmacy, the Company is currently advancing the development of SBFM-PL4 through the in vitro testing stage to be followed by mice studies before entering clinical trials on COVID-19 patients.

## **About Sunshine Biopharma**

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.

## **Safe Harbor Forward-Looking Statements**

*This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.*

## **For Additional Information Contact:**

Camille Sebaaly, CFO

Sunshine Biopharma Inc.

Direct Line: 514-814-0464

[camille.sebaaly@sunshinebiopharma.com](mailto:camille.sebaaly@sunshinebiopharma.com)

[www.sunshinebiopharma.com](http://www.sunshinebiopharma.com)